呼吸器・免疫内科学

白山　敬之Shiroyama Takayuki M.D., PhD

略歴

所属学会

日本内科学会、日本呼吸器学会、日本呼吸器内視鏡学会、日本肺癌学会、日本化学療法学会、日本静脈経腸栄養学会

主要論文

• Adachi Y, Shiroyama T, Yamaguchi Y, Murakami T, Hirata H, Amiya S, Niitsu T, Noda Y, Hara R, Enomoto T, Morita T, Kato Y, Uchiyama A, Takeda Y, Kumanogoh A. Predicting recurrence of respiratory failure in critically ill patients with COVID-19: A preliminary study. J Infect. 2021 Jan 24. doi: 10.1016/j.jinf.2021.01.016.
• Shiroyama T, Hirata H, Nagatomo I, Takeda Y, Kumanogoh A. Pulmonary metastases of lung adenocarcinoma mimicking COVID-19 pneumonia. J Thorac Dis. 2020 Oct;12(10):6125-6126.
• Edahiro R, Shiroyama T, Hijiki S, Nojima S, Shirai Y, Koyama S, Kumanogoh A. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment. Lung Cancer. 2020 Feb;140:116-117.
• Masuhiro K, Shiroyama T, Nagatomo I, Kumanogoh A. Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment. J Thorac Oncol. 2019 May;14(5):e108-e109.
• Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, Masuhiro K, Yaga M, Iwahori K, Takeda Y, Kida H, Kumanogoh A. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019 Feb 21;9(1):2447.
• Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T. Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Res. 2018 Aug;38(8):4723-4729.
• Nasu S, Suzuki H, Shiroyama T, et al. Skin Rash Can Be a Useful Marker for Afatinib Efficacy. Anticancer Res. 2018 Mar;38(3):1783-1788.
• Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 2018 Jan;7(1):13-20.
• Tamiya M, Tamiya A, Shiroyama T, et al. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naive advanced non-squamous non-small cell lung cancer with EGFR mutations. Invest New Drugs. 2017 Nov 4. doi: 10.1007/s10637-017-0527-z.
• Shiroyama T, Tamiya M, Minami S, et al. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study. Cancer Chemother Pharmacol. 2017 Sep;80(3):461-467.
• Shiroyama T, Okamoto N, Tamiya M, et al. Effective Management of Persistent Pneumothorax Using a ThopazR Digital Drainage System Combined with an Endobronchial Watanabe Spigot. Intern Med. 2016;55(6):663-5.
• Shiroyama T, Okamoto N, Suzuki H, et al. Usefulness of high suction pressure for sufficient tissue collection during endobronchial ultrasound guided transbronchial needle aspiration. PLoS One. 2013 Dec 5;8(12):e82787.
• Tamiya A, Tamiya M, Shiroyama T, Kanazu M, Hirooka A, Tsuji T, Morishita N, Asami K, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Hirashima T, Atagi S, Kawase I. Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol. 2013 Apr;24(4):980-5.
• Shiroyama T, Kijima T, Komuta K, et al. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol. 2012 Dec;70(6):783-9.
• Shiroyama T, Komuta K, Imamura F, et al. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer. 2011 Oct;74(1):85-8.